Purpose Hyperhomocysteinaemia has been linked to macrovascular disease. Our aim was to investigate whether there is a relationship between fasting plasma total homocysteine levels and retinal vascular disease.
Methods
We measured the homocysteine levels in 70 patients with arterial or venous retinal vessel occlusion and compared them with the levels in 85 controls without evidence of ischaemic heart disease. Homocysteine levels were determined by high-performance liquid chromatography with electrochemical detection and compared after logarithmic transformation.
Results Homocysteine levels were found by univariate analysis (unpaired two-tailed t-test) to be significantly higher in the group with retinal artery occlusion than the group with retinal vein occlusion ( p = 0.045) and in both groups compared with controls (18.4 and 13.8 vs 9.5 fLmol/l; p = 0.0002 and < 0.0001, respectively).
The controls, however, were significantly younger than the subjects (51.5 ± 15.4 vs 66.2 ± 11.9 years; p < 0.0001), but analysis of the results by age revealed significant differences between the groups and controls for the seventh decade (vein occlusions, p = 0.05) and for the eighth decade (artery occlusions, p = 0.037). 
Controls
The 85 controls were laboratory staff and patients without known ischaemic heart disease attending other outpatient clinics at Heartlands Hospital.
Measurement of homocysteine
HCySH was measured by high-pressure liqUid chromatography (HPLC) with electrochemical detection, as described previously. 9 Basically, plasma samples were reduced with dithiothreitol to liberate homocysteine, the protein was precipitated by sulphosalicylic acid and the supernatant analysed.
Statistics
All univariate analyses were by unpaired two-tailed Approval for the study was obtained from the hospital ethics committee.
Results
We measured the fasting plasma total HCySH levels in a group of consecutive patients with RVOD and compared these with the controls. All the groups had equal male/ female ratios and there were no significant differences between the RVOD subgroups in age, serum total cholesterol, triglycerides, glucose, cigarettes smoked or ethanol intake. Table 1 shows that the control group, however, was significantly younger than the RVOD group (p < 0.0001).
Univariate analysis revealed that HCySH levels were significantly raised in patients compared with controls (RAO 18.4 ± 1.5 and all RVO 13.8± 1.5 vs 9.5 ± 1.5 ILmol/l; p = 0.0002 and < 0.0001, respectively). As the control group was younger and HCySH levels are known to increase with age we reanalysed the data grouping patients and controls into decades of age. Fig. 1 shows that HCySH levels tend to increase linearly with age in both the RVO group and controls (7/10 of the RAO group was aged between 70 and 79 years and are shown as a single point). Comparing the means for each group by age yielded significant differences between RVO (n = 13) and controls (n = 22) for the seventh decade (p = 0.05) and between the RAO group (n = 7) and controls (n = 7) for the eighth decade (p = 0.037).
Further analysis of the RVOD group showed that those patients with CRVO (n = 36) had significantly higher HCySH levels than BRVO patients (n = 24) (15. 
